Cargando…

Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers

BACKGROUND: We present a radiomics-based model for predicting response to pembrolizumab in patients with advanced rare cancers. METHODS: The study included 57 patients with advanced rare cancers who were enrolled in our phase II clinical trial of pembrolizumab. Tumor response was evaluated using Res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Colen, Rivka R, Rolfo, Christian, Ak, Murat, Ayoub, Mira, Ahmed, Sara, Elshafeey, Nabil, Mamindla, Priyadarshini, Zinn, Pascal O, Ng, Chaan, Vikram, Raghu, Bakas, Spyridon, Peterson, Christine B, Rodon Ahnert, Jordi, Subbiah, Vivek, Karp, Daniel D, Stephen, Bettzy, Hajjar, Joud, Naing, Aung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051405/ https://www.ncbi.nlm.nih.gov/pubmed/33849924 http://dx.doi.org/10.1136/jitc-2020-001752

Ejemplares similares

Author response to Cunha et al
por: Colen, Rivka R, et al.
Publicado: (2021)

Phase 2 study of pembrolizumab in patients with advanced rare cancers
por: Naing, Aung, et al.
Publicado: (2020)

T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy
por: Stephen, Bettzy, et al.
Publicado: (2023)

Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors
por: Tapia, Coya, et al.
Publicado: (2020)

MRI-Based Radiomics and Radiogenomics in the Management of Low-Grade Gliomas: Evaluating the Evidence for a Paradigm Shift
por: Habib, Ahmed, et al.
Publicado: (2021)

Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma
por: Habra, Mouhammed Amir, et al.
Publicado: (2019)

Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial
por: Raghav, Kanwal P, et al.
Publicado: (2022)

Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas
por: Jimenez, Camilo, et al.
Publicado: (2020)

Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory
por: Mendoza, Tito, et al.
Publicado: (2020)

Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial
por: Mendoza, Tito R., et al.
Publicado: (2022)

T057: Circulating tumor DNA in classical Hodgkin lymphoma patients treated with pembrolizumab and chemotherapy: dynamic response assessment and correlation with baseline total metabolic tumor volume
por: Lynch, Ryan C., et al.
Publicado: (2022)

Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study
por: Majd, Nazanin, et al.
Publicado: (2020)

P061: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
por: Borchmann, Peter, et al.
Publicado: (2022)

T058: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment
por: Timmerman, John, et al.
Publicado: (2022)

A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma
por: Nze, Chijioke, et al.
Publicado: (2023)

Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma
por: Nishihori, Taiga, et al.
Publicado: (2022)

Targeting the indoleamine 2,3-dioxygenase pathway in cancer
por: Moon, Yong Wha, et al.
Publicado: (2015)

Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer
por: Chun, Brie, et al.
Publicado: (2022)

Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab
por: Watson, Geoffrey Alan, et al.
Publicado: (2022)

Evaluation of tumor antigen-specific antibody responses in patients with metastatic triple negative breast cancer treated with cyclophosphamide and pembrolizumab
por: Routh, Eric D, et al.
Publicado: (2023)

Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
por: Cristescu, Razvan, et al.
Publicado: (2022)

Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial
por: How, Jeffrey A., et al.
Publicado: (2021)

Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials
por: How, Jeffrey A., et al.
Publicado: (2022)

Impact of immune-related adverse events on the therapeutic efficacy of pembrolizumab in urothelial carcinoma: a multicenter retrospective study using time-dependent analysis
por: Kawai, Taketo, et al.
Publicado: (2022)

Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
por: Haddad, Robert I, et al.
Publicado: (2022)

Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)
por: Ricciuti, Biagio, et al.
Publicado: (2021)

PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis
por: Lo Russo, Giuseppe, et al.
Publicado: (2023)

Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer
por: de Miguel-Perez, Diego, et al.
Publicado: (2022)

Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer
por: Egelston, Colt, et al.
Publicado: (2021)

Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
por: Goswami, Meghali, et al.
Publicado: (2022)

Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer
por: Alessi, Joao V, et al.
Publicado: (2021)

T-cell agonists in cancer immunotherapy
por: Choi, Yeonjoo, et al.
Publicado: (2020)

Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial
por: Ellingsen, Espen B., et al.
Publicado: (2023)

Corrigendum to “Automated Feature Extraction in Brain Tumor by Magnetic Resonance Imaging Using Gaussian Mixture Models”
por: Chaddad, Ahmad, et al.
Publicado: (2017)

Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study
por: Thein, Kyaw Z., et al.
Publicado: (2022)

Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma
por: Bedrose, Sara, et al.
Publicado: (2020)

Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma
por: Lurain, Kathryn, et al.
Publicado: (2021)

Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors
por: Hurkmans, Daan P., et al.
Publicado: (2021)

IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation
por: Rozeman, Elisa A, et al.
Publicado: (2023)

Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study
por: Taylor, Matthew H., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dgo2380amhl2baoiaghhgqa27d